Primary Job Title CEO Primary Organization Ribometrix
Location Boston, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male
Investor Type
LinkedIn View on LinkedIn
Mike has more than 20 years of experience in the biotechnology industry, with the last 14 focused on creating and operating early stage therapeutic-focused companies. He was most recently Chief Operating Officer at Decibel Therapeutics, a biotechnology company focused on broadly treating hearing disorders. Mike’s involvement at Decibel was part of
his work as an Entrepreneur-in-Residence at Third Rock Ventures; he led a team that created Decibel’s business plan resulting in a $52 M Series A round. Prior to Decibel, Mike was Chief Operating Officer at Ember Therapeutics, a Third Rock Ventures company focused on obesity and diabetes, and Chief Business Officer at Link Medicine, a neurodegeneration focused biotechnology company that was sold to Astra Zeneca. Mike was also a founder and VP of Discovery at Epizyme Therapeutics, a company focused on epigenetic modulators that is now a publicly traded company, and VP of Discovery at Hypnion, Inc a sleep disorder company that was sold to Lilly in 2007 for $325 million. Mike also spent two years as a biotechnology analyst at Bank of America Securities. He started his career at Millennium Pharmaceuticals, where he was project leader for multiple programs.
